Oro Valley-based Ventana Medical Systems said it is introducing a first-of-its-kind, fully-automated sample staining technique that will allow researchers to examine two key indicators related to cancer in the same section of tumor tissue.

Ventana said studying miRNA — micro ribonucleic acid — and proteins together in tumors allows researchers to study how their relationship plays a role in driving tumor cell growth in many cancer types including breast, lung, prostate and colorectal cancers.

The application, which is designed for use with Ventana’s Discovery Ultra automated slide-staining instrument, also uses non-enzyme pretreatments to better preserve tissue structure, said Ventana, part of Swiss drug giant Roche.

Check out the entire news release, with photos and videos, at tinyurl.com/98ewwvr